Keytruda: Uses, Dosage, Side Effects, Warnings - Drugs.com
Dec 23, 2025 · Keytruda (pembrolizumab) is a PD-1 inhibitor treating 20+ cancer types, including melanoma, lung, head/neck, breast, gastric, colorectal, and kidney cancers. It is administered …
Infusion Information and Resources for KEYTRUDA® …
View tips and resources that may help while receiving KEYTRUDA® (pembrolizumab) including what to expect with your first infusion appointment and what to know about your treatment …
Keytruda (pembrolizumab): Side effects, uses, cost, and more
Aug 21, 2025 · Keytruda is a brand-name infusion approved to treat several types of cancer. Learn about side effects, warnings, dosage, and more.
Keytruda (pembrolizumab) - Uses, Side Effects, and More
Dec 18, 2024 · Keytruda can cause infusion reactions that can be serious and even life-threatening when it is given to you. Your infusion may need to be slowed or stopped if you …
Keytruda: How It’s Administered, Dosage, and More - Healthline
Sep 25, 2025 · Learn about how the drug is given, how often you’ll receive doses, and more. You’ll receive Keytruda as an IV infusion. A doctor, nurse, or another healthcare professional …
Preparation, Storage and Administration of KEYTRUDA® …
Health care professionals may find information about preparation, storage and administration of KEYTRUDA® (pembrolizumab). See step-by-step instructions.
KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving …
Pembrolizumab (intravenous route) - Side effects & uses
Nov 1, 2025 · The infusion will be given every 3 or 6 weeks, depending on your dose. If you are also receiving chemotherapy for NSCLC, pembrolizumab will be given first on the same day.
Pembrolizumab (Keytruda): Uses & Side Effects - Cleveland Clinic
Pembrolizumab Injection Pembrolizumab is a monoclonal antibody that treats certain types of cancer. The brand name of this medication is Keytruda®. A healthcare provider will give you …
Administration Administer infusion solution intravenously over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or...